Citations 4
1563: OUTCOMES OF REINTUBATED PATIENTS IN THE TRAUMA INTENSIVE CARE UNIT
Mahony, C , Heller, Stephanie F. , Ballinger, Beth A. , Park, Myung, Loomis, Erica, Bannon, Michael P., Rivera, Mariela , Traynor, Michael D.
Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 785-785
197: ESTRADIOL AND DIHYDROTESTOSTERONE LEVELS IN COVID-19 PATIENTS
Goswami, Julie , Price-Troska, Tammy, Lundell, Kaitlin, Ballinger, Beth A. , Loomis, Erica, Heller, Stephanie F. , Stephens, Daniel , Spears, Grant M. , Bailey, Kent R. , Chaudry, Irshad H. , Park, Myung, MacArthur, Taleen A. , Stephens, Daniel
Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 82-82
Endogenous Procoagulant Activity in Trauma Patients and Its Relationship to Trauma Severity
Prior, Shannon M., Park, Myung, Mann, Kenneth G. , Butenas, Saulius
TH Open | January 18, 2019 | Volume: 03 | Issue: 01 | Pages: e10-e19
Background It has been observed that trauma patients have elevated plasma procoagulant activity that could be assigned to an elevated concentration of tissue factor (TF). However, in many instances there is a discrepancy between the levels of TF and the procoagulant activity observed. We hypothesized that factor XIa (FXIa) could be responsible for this additional activity and that the presence and levels of both proteins could correlate with trauma severity. Methods Citrate plasma from 98 trauma patients (47 blunt, 17 penetrating, and 34 thermal) were evaluated in clotting assays for the presence of FXIa and TF activity using respective inhibitory antibodies. Results When the three trauma patient groups were divided into two cohorts (Injury Severity Score [ISS] > 25 and ISS ≤ 25), higher frequencies and concentrations of both TF and FXIa were observed for all the more severe injury subgroups. Conclusions The majority of trauma patients have active FXIa in their plasma, with a significant fraction having active TF as well. Additionally, both TF and FXIa frequency and concentration directly relate to trauma severity. These data suggest the use of these two proteins as potential markers for the stratification of trauma patients.
Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
Rahaghi, Franck , Alnuaimat, Hassan, Awdish, Rana , Balasubramanian, Vijay , Bourge, Robert C. , Butler, John, Cauthen, C. Gregory, Chakinala, Murali M. , deBoisblanc, Bennett P., Eggert, Michael, Engel, Peter A., Feldman, Jeremy, McConnell, J.W. , Park, Myung, Sager, Jeffrey S., Sood, Namita , Palevsky, Harold I. , Burger, Charles D.
Pulmonary Circulation | July 17, 2017 | Volume: 7 | Issue: 3 | Pages: 702-711
In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment‐related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add‐on therapy, drug–drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real‐world issues in using macitentan to treat patients with PAH.